Pay in 4 interest-free payments of $5.06 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
de Oliveira Silva et al., 2019
Comparable to other peptides linked to fatty acids (e.g., the insulins detemir and degludec, the GLP-1RA liraglutide and semaglutide), the fatty acid side chain allows binding to albumin after subcutaneous injection, slows enzymatic degradation and prolongs biological half-life ( In vitro signaling studies demonstrated that tirzepatide was able to activate the GIP receptor with comparable potency to native GIP ( in vitro and in vivo models used, tirzepatide was able to stimulate glucose-dependent insulin secretion via GIP and/or GLP-1 receptor activation
Realworld studies show that side effects are almost universal: In a prospective cohort of 77 patients with gastric, periampullary, colorectal, and breast cancers, 97.4% reported at least one side effect over six months
For those using a GLP-1, the 5-year survival rate was 86.3%, and the 10-year survival rate was 75.5%
Timing Follow-up Marker A1c Why it matters Tracks longer-term glucose control because GH-axis changes may affect insulin sensitivity
,aspect=ignore)
